Xtant Medical Holdings, Inc. (XTNT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 8, 2024, announces the financial results for Xtant Medical Holdings, Inc. for the three and six months ended June 30, 2024. The filing serves to disseminate the press release (Exhibit 99.1) detailing the Company's second-quarter performance.
Key Financial Metrics
The filing text references a press release titled "Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%" but does not explicitly state the absolute dollar values for revenue, net loss, cash flow, or debt within the body of this 8-K document.
- Revenue Growth: The press release title indicates a 48% increase in revenue for the second quarter of 2024 compared to the prior period.
- Non-GAAP Measures: The Company utilizes Adjusted EBITDA as a key performance metric. This measure adjusts net loss by adding back depreciation, amortization, interest, taxes, non-cash compensation, acquisition-related expenses, fair value adjustments, and unrealized foreign currency translation gains/losses.
- GAAP vs. Non-GAAP: The filing notes that a reconciliation of Non-GAAP Adjusted EBITDA to Net Loss is provided in the attached press release (Exhibit 99.1), which is not included in the text of this summary.
Material Changes
The primary material change highlighted in the filing is the significant revenue growth of 48% for the quarter ended June 30, 2024. The filing does not provide specific comparative figures for the prior period to quantify the absolute change in profit or cash flow.
Management Commentary and Non-GAAP Rationale
Management employs Adjusted EBITDA to assess core operational performance, facilitate budgeting decisions, and enable period-over-period comparisons by excluding non-recurring or non-cash items. Specific exclusions and their rationales include:
- Non-cash compensation: Excluded due to reliance on unpredictable market valuations of equity awards.
- Acquisition-related expenses: Excluded as they are not reflective of ongoing operations (e.g., legal, accounting, transition fees).
- Acquisition-related fair value adjustments: Excluded to focus on core profitability.
- Unrealized foreign currency translation: Excluded as it does not reflect ongoing operating results.
Note: The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly provided.
Investor Verification Checklist
- Verify the absolute revenue and net loss figures for Q2 2024 in the attached Exhibit 99.1 (Press Release), as they are not listed in this 8-K text.
- Review the reconciliation table in the press release to understand the specific dollar adjustments made to derive Adjusted EBITDA from Net Loss.
- Confirm the cash flow and liquidity position (cash on hand, debt obligations) in the full press release or the subsequent 10-Q filing, as this 8-K does not provide these specific numbers.
- Assess the sustainability of the 48% revenue growth by reviewing the segment breakdown and product mix details in the full earnings release.